Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 9, Issue 6, Pages 785-793Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.09.43
Keywords
HGF; HPRC; Met; RCC; renal cell carcinoma; targeted therapy; TFE3
Categories
Funding
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
Ask authors/readers for more resources
Renal cell carcinoma (RCC), the most common form of kidney cancer, accounts for 3% of all adult malignancies and its incidence has significantly increased over the last 20 years. RCC claims 13,000 lives annually in the USA and more than 100,000 worldwide. A better understanding of the molecular basis of RCC has facilitated the development of novel and more selective therapeutic approaches. An important role in RCC oncogenesis is played by the receptor for HGF, Met, which has attracted considerable attention, more recently as a molecular target for cancer therapy, and several drugs selectively targeting this pathway are now in clinical trials. This review will focus on efforts to understand the role of the Met signaling pathway in renal cancer and how this has contributed to the development of potent and selective drug candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available